Jaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note published on Friday. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Price Performance

JAGX stock opened at $4.63 on Friday. The company has a quick ratio of 1.39, a current ratio of 1.89 and a debt-to-equity ratio of 1.84. The business has a 50-day moving average of $9.61 and a 200-day moving average of $9.84. Jaguar Health has a fifty-two week low of $3.07 and a fifty-two week high of $43.53.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($3.60) EPS for the quarter. The company had revenue of $2.35 million for the quarter. Jaguar Health had a negative return on equity of 642.15% and a negative net margin of 377.95%. On average, equities analysts anticipate that Jaguar Health will post -5.42 EPS for the current fiscal year.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.